BTAI
Price
$5.15
Change
+$0.17 (+3.41%)
Updated
Aug 25, 04:59 PM (EDT)
Capitalization
75.11M
CASI
Price
$2.42
Change
+$0.06 (+2.54%)
Updated
Aug 25, 04:59 PM (EDT)
Capitalization
37.65M
Interact to see
Advertisement

BTAI vs CASI

Header iconBTAI vs CASI Comparison
Open Charts BTAI vs CASIBanner chart's image
BioXcel Therapeutics
Price$5.15
Change+$0.17 (+3.41%)
Volume$11.28K
Capitalization75.11M
CASI Pharmaceuticals
Price$2.42
Change+$0.06 (+2.54%)
Volume$387
Capitalization37.65M
BTAI vs CASI Comparison Chart in %
Loading...
BTAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CASI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BTAI vs. CASI commentary
Aug 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BTAI is a Hold and CASI is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 26, 2025
Stock price -- (BTAI: $4.98 vs. CASI: $2.36)
Brand notoriety: BTAI and CASI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BTAI: 35% vs. CASI: 4%
Market capitalization -- BTAI: $75.11M vs. CASI: $37.65M
BTAI [@Biotechnology] is valued at $75.11M. CASI’s [@Biotechnology] market capitalization is $37.65M. The market cap for tickers in the [@Biotechnology] industry ranges from $99.72B to $0. The average market capitalization across the [@Biotechnology] industry is $1.86B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BTAI’s FA Score shows that 0 FA rating(s) are green whileCASI’s FA Score has 0 green FA rating(s).

  • BTAI’s FA Score: 0 green, 5 red.
  • CASI’s FA Score: 0 green, 5 red.
According to our system of comparison, both BTAI and CASI are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BTAI’s TA Score shows that 6 TA indicator(s) are bullish while CASI’s TA Score has 6 bullish TA indicator(s).

  • BTAI’s TA Score: 6 bullish, 4 bearish.
  • CASI’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, CASI is a better buy in the short-term than BTAI.

Price Growth

BTAI (@Biotechnology) experienced а -9.12% price change this week, while CASI (@Biotechnology) price change was -0.84% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.14%. For the same industry, the average monthly price growth was +18.77%, and the average quarterly price growth was +29.32%.

Industries' Descriptions

@Biotechnology (+2.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BTAI($75.1M) has a higher market cap than CASI($37.6M). CASI (-16.608) and BTAI (-16.756) have similar YTD gains . BTAI has higher annual earnings (EBITDA): -34.61M vs. CASI (-38.42M). BTAI has more cash in the bank: 17.4M vs. CASI (12.7M). CASI has less debt than BTAI: CASI (18.5M) vs BTAI (109M). CASI has higher revenues than BTAI: CASI (31.4M) vs BTAI (868K).
BTAICASIBTAI / CASI
Capitalization75.1M37.6M200%
EBITDA-34.61M-38.42M90%
Gain YTD-16.756-16.608101%
P/E RatioN/AN/A-
Revenue868K31.4M3%
Total Cash17.4M12.7M137%
Total Debt109M18.5M589%
FUNDAMENTALS RATINGS
BTAI vs CASI: Fundamental Ratings
BTAI
CASI
OUTLOOK RATING
1..100
4950
VALUATION
overvalued / fair valued / undervalued
1..100
78
Overvalued
70
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
3438
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
507

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CASI's Valuation (70) in the Biotechnology industry is in the same range as BTAI (78). This means that CASI’s stock grew similarly to BTAI’s over the last 12 months.

CASI's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as BTAI (100). This means that CASI’s stock grew similarly to BTAI’s over the last 12 months.

CASI's SMR Rating (100) in the Biotechnology industry is in the same range as BTAI (100). This means that CASI’s stock grew similarly to BTAI’s over the last 12 months.

BTAI's Price Growth Rating (34) in the Biotechnology industry is in the same range as CASI (38). This means that BTAI’s stock grew similarly to CASI’s over the last 12 months.

BTAI's P/E Growth Rating (100) in the Biotechnology industry is in the same range as CASI (100). This means that BTAI’s stock grew similarly to CASI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BTAICASI
RSI
ODDS (%)
Bearish Trend 4 days ago
84%
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
87%
Bullish Trend 4 days ago
77%
Momentum
ODDS (%)
Bullish Trend 4 days ago
74%
Bullish Trend 4 days ago
82%
MACD
ODDS (%)
Bullish Trend 4 days ago
83%
N/A
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 4 days ago
83%
Advances
ODDS (%)
Bullish Trend 5 days ago
81%
Bullish Trend 5 days ago
83%
Declines
ODDS (%)
Bearish Trend 12 days ago
90%
Bearish Trend 7 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 4 days ago
88%
Aroon
ODDS (%)
Bullish Trend 4 days ago
69%
Bullish Trend 4 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
BTAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CASI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
QRHC1.680.09
+5.66%
Quest Resource Holding Corp
CRUS117.383.41
+2.99%
Cirrus Logic
AMAT162.492.65
+1.66%
Applied Materials
LANV2.110.03
+1.44%
Lanvin Group Holdings Limited
COLL39.11-0.41
-1.04%
Collegium Pharmaceutical

BTAI and

Correlation & Price change

A.I.dvisor indicates that over the last year, BTAI has been loosely correlated with ORMP. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if BTAI jumps, then ORMP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BTAI
1D Price
Change %
BTAI100%
-4.78%
ORMP - BTAI
44%
Loosely correlated
+3.88%
AXON - BTAI
42%
Loosely correlated
+0.36%
INO - BTAI
39%
Loosely correlated
+2.62%
ARRY - BTAI
37%
Loosely correlated
+8.10%
SYBX - BTAI
37%
Loosely correlated
+4.29%
More

CASI and

Correlation & Price change

A.I.dvisor tells us that CASI and ASND have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CASI and ASND's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CASI
1D Price
Change %
CASI100%
-4.45%
ASND - CASI
33%
Poorly correlated
+0.78%
NEVPF - CASI
31%
Poorly correlated
N/A
RIGL - CASI
29%
Poorly correlated
-1.17%
BTAI - CASI
29%
Poorly correlated
-4.78%
SRPT - CASI
28%
Poorly correlated
+0.80%
More